To summarize the therapeutic effect of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer in a real-world setting, we attempted to identify potential molecular biomarkers or clinical factors that reflected the therapeutic effect. This evidence concerns the gene CD274 and non-small cell lung carcinoma.